GSK
GlaxoSmithKline Pharmaceuticals reported consolidated Q1 net profit of ₹237.18 cr for the quarter ended June 30, 2026, up about 15.7% from ₹205 cr a year earlier, with revenue from operations of ₹938.44 cr. The board re-appointed Bhushan Akshikar as managing director for two years and updated directors after Subesh Williams’ resignation and Karine J F Natland’s appointment.
Over the past 7 days, alphai's AI scored 1 news story mentioning GSK.L (GSK). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Profit growth plus board/MD continuity is a near-term positive catalyst for sentiment, but no guidance or valuation change is provided.
alphai scores every news story that mentions GSK.L with an AI model for sentiment and relevance, and aggregates insider trades from GSK's SEC EDGAR Form 4 filings. Figures refresh continuously.
GlaxoSmithKline Pharmaceuticals reported consolidated Q1 net profit of ₹237.18 cr for the quarter ended June 30, 2026, up about 15.7% from ₹205 cr a year earlier, with revenue from operations of ₹938.44 cr. The board re-appointed Bhushan Akshikar as managing director for two years and updated directors after Subesh Williams’ resignation and Karine J F Natland’s appointment.
5 min read
